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Abstract
Introduction Saliva metabolites are suggested to reflect the health status of an individual in humans. The same could be true 
with the dog (Canis lupus familiaris), an important animal model of human disease, but its saliva metabolome is unknown. 
As a non-invasive sample, canine saliva could offer a new alternative material for research to reveal molecular mechanisms 
of different (patho)physiological stages, and for veterinary medicine to monitor dogs’ health trajectories.
Objectives To investigate and characterize the metabolite composition of dog and human saliva in a non-targeted manner.
Methods Stimulated saliva was collected from 13 privately-owned dogs and from 14 human individuals. We used a non-
targeted ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-qTOF-MS) 
method to measure metabolite profiles from saliva samples.
Results We identified and classified a total of 211 endogenous and exogenous salivary metabolites. The compounds included 
amino acids, amino acid derivatives, biogenic amines, nucleic acid subunits, lipids, organic acids, small peptides as well as 
other metabolites, like metabolic waste molecules and other chemicals. Our results reveal a distinct metabolite profile of dog 
and human saliva as 25 lipid compounds were identified only in canine saliva and eight dipeptides only in human saliva. In 
addition, we observed large variation in ion abundance within and between the identified saliva metabolites in dog and human.
Conclusion The results suggest that non-targeted metabolomics approach utilizing UHPLC-qTOF-MS can detect a wide range 
of small compounds in dog and human saliva with partially overlapping metabolite composition. The identified metabolites 
indicate that canine saliva is potentially a versatile material for the discovery of biomarkers for dog welfare. However, this 
profile is not complete, and dog saliva needs to be investigated in the future with other analytical platforms to characterize 
the whole canine saliva metabolome. Furthermore, the detailed comparison of human and dog saliva composition needs to 
be conducted with harmonized study design.
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LPC  Lysophosphatidylcholine
LPE  Lysophosphatidylethanolamine
PC  Phosphatidylcholine
PE  Phosphatidylethanolamine
phe  Phenylalanine
pro  Proline
pyroglu  Pyroglutamic acid
ser  Serine
TAG  Triacylglycerol
thr  Threonine
tyr  Tyrosine
val  Valine
1 Introduction
Human saliva has been studied and characterized extensively 
in recent years. Most of the saliva is water (over 99%) con-
taining a variety of electrolytes, different kinds of proteins as 
well as low molecular weight (< 1500 Da of mass) metabo-
lites (Dame et al. 2015; Humphrey and Williamson 2001; 
Gardner et al. 2020). Mucus, epithelial and blood cells, food 
remainders and traces of medications or chemical products 
are also found in saliva (Aps and Martens 2005; Elmongy 
and Abdel-Rehim 2016). Moreover, biological material such 
as DNA and bacteria with their metabolites exist in saliva 
(Cuevas-Cordoba and Santiago-Garcia 2014).
Since saliva is rich in small molecules and given its 
role as “a mirror of the body”, there is a growing interest 
towards saliva usage as a non-invasive sample material for 
monitoring health trajectories to aid diagnosis or reveal the 
molecular mechanisms of disease pathologies. The same 
applies to domestic dogs which suffer from similar diseases 
to humans such as metabolic diseases, chronic inflammation, 
and cancers, manifested as diabetes (O’Kell et al. 2017), 
inflammatory bowel disease (Minamoto et al. 2015) and leu-
kemia (Breen and Modiano 2008), respectively. Physiologi-
cal similarity with humans and the large size of the canine 
have been reasons for the rise of these animals to one of the 
biomedical models alongside the rodents, for example in the 
study of genomics (Hytonen and Lohi 2016; van Steenbeek 
et al. 2016) and behavior (Puurunen et al. 2018). Despite the 
rising interest in dogs and saliva metabolomics, there is no 
data available for the canine saliva metabolome.
Humans share the same anatomy and salivary gland 
structure with dogs, except for dogs’ zygomatic glands. The 
basic functions of saliva, such as lubrication, maintenance 
of oral homeostasis and dental welfare as well as bacteri-
cidal effects against pathogens, resemble each other (Dame 
et al. 2015; de Sousa-Pereira et al. 2015; Humphrey and Wil-
liamson 2001). Moreover, dogs use panting and evaporative 
cooling as the major function when exposed to heat and/or 
exercise (Goldberg et al. 1981). Differences between human 
and canine saliva have been revealed in the comparison of 
the proteome signature where, for example, cystatins with 
antimicrobial properties have been recognized in lower lev-
els in the saliva of canines compared to saliva of humans 
(Sanguansermsri et al. 2018). In addition, different antimi-
crobial protein family members are identified in human and 
dog saliva, such as cathelicidin 1, cathelicidin antimicrobial 
peptide and CRISP1 in dog saliva, whereas cathelicidins 
were not detected in healthy humans but CRISP3 was (de 
Sousa-Pereira et al. 2015).
Several studies of the human salivary metabolome link 
it to various conditions, including oral and breast cancers 
(Sugimoto et al. 2010), type 2 diabetes (Barnes et al. 2014) 
and Sjögren’s syndrome (Mikkonen et al. 2013). Therefore, 
also the salivary metabolome of the dog could reflect the 
metabolic activity of canines’ oral cavity and total body. In 
this study, we compared the metabolome of dog and human 
saliva utilizing UHPLC-qTOF-MS -based non-targeted 
metabolomics approach. We aimed to identify a wide range 
of saliva metabolites to explore the metabolic profiles of 
both species and their overlap.
2  Materials and methods
2.1  Animals and human participants
Voluntary Finnish dog owners were recruited for the canine 
saliva donation. The saliva collection was conducted from 
13 privately-owned dogs with the owners’ written consent 
and presence. The dogs were healthy referring no disease 
with one exception (cataract) and were not subjected to any 
drug treatment according to their owners. The breeds were 
Belgian Sheepdog (n = 2), Belgian Tervueren (n = 2), Wei-
maraner (n = 2), Rottweiler (n = 3), Golden Retriever (n = 2) 
and Flat-Coated Retriever (n = 2). The age of the dogs varied 
from 1.2 years to 9.3 years. The mean age was 5.5 years and 
SD 2.5 years. The number of males were 5 and females 8. 
Two of the female dogs were neutered.
Human saliva samples were collected from 14 healthy, 
non-smoking females, aged between 30 and 70 years (mean 
age 53 years, SD 11) who were recruited from the dental 
education clinic of Kuopio University Hospital. The vol-
unteers had no recent history of systemic diseases or were 
not taking any medication. Inclusion criteria were healthy 
subjects, with normal excretion of saliva and no medica-
tions. Exclusion criteria were smokers, wearing removable 
dentures, having systemic diseases or medication, having a 
treatment history for cancer, or being incapable of communi-
cation. Out of all the patients examined, no males met these 
criteria. At the time of the study, every subject underwent 
an oral and dental examination performed by a dentist, and 
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their oral health were good, no gingivitis, missing/broken 
teeth or caries.
2.2  Collection of saliva samples
Canine saliva samples were collected between 9 to 11 a.m. 
by the same person at the dog’s home. The dogs were fasted 
and rested 12 h before sampling. Saliva was collected with-
out causing any stress or harm to dogs as follows. Salivation 
was stimulated with prospect of food, i.e. the dog could see 
or sniff the treat but was not allowed to eat it. Saliva was col-
lected under the tongue and from the surface of the mucosal 
lining of lips and cheek straight to 1.5 ml Eppendorf tube. 
The maximum collection time was four minutes. No contam-
inations, e.g. hair and blood, were observed in visual inspec-
tion. Immediately after sampling, proteins were precipitated, 
and metabolites extracted with two volumes of acetonitrile 
mixed with 1 volume of saliva simultaneously mixing gently 
in vortex and finally at maximum speed 10 s. Samples were 
kept on ice during shipping and stored in − 20 °C 3–5 days 
prior to metabolomics analysis.
Human saliva samples were collected at least one hour 
after eating and drinking between 9 and 11 a.m. Stimulated 
saliva was collected using the standard technique according 
to Navazesh (1993) as follows. The saliva flow was stimu-
lated by chewing a paraffin wax (1 g; Orion Diagnostica, 
Espoo, Finland) for 30 s, followed by the collection of the 
produced saliva into a glass cup for five minutes. Saliva 
samples were transported to the laboratory on ice, and then 
clarified by centrifugation (3000×g, 20 min, + 4 °C). The 
supernatants were stored at − 20 °C for later use.
2.3  Sample preparation
Dog and human saliva samples were thawed on ice. Human 
saliva samples were precipitated and extracted similarly as 
dog saliva (200 µL of saliva and 400 µL of acetonitrile). All 
samples were centrifuged (10,600×g, 5 min, + 4 °C), and 
the supernatants were filtrated through 0.2 µm Acrodisc® 
Syringe Filters with a PTFE membrane (PALL Corporation, 
Ann Arpor, MI) prior subjecting to the LC–MS analyses. 
Quality control (QC) samples were made separately from 
dog and human samples by mixing aliquots of 30 µl from 
every dog or human supernatant to one tube. QC mixed sam-
ple contained aliquots from every dog and human sample 
mixed into one tube.
HPLC-grade acetonitrile (VWR Chemicals, Fontenay-
sous-Bois, France) was used for sample preparation. LC–MS 
grade methanol (Riedel-de Haën™, Honeywell, Seelze, 
Germany), HPLC-grade acetonitrile (VWR Chemicals, 
Fontenay-sous-Bois, France), LC–MS grade formic acid 
(Fluka™, Honeywell, Seelze, Germany), ammonium for-
mate (Fluka™, Honeywell, Seelze, Germany) and class 1 
ultra-pure water (ELGA Purelab ultra Analytical, UK) were 
used for mobile phase eluents in RP and HILIC chromato-
graphic separation.
2.4  UHPLC‑qTOF‑MS analysis
The samples were analyzed by a 1290 LC system coupled 
to a 6540 UHD accurate-mass qTOF spectrometer (Agilent 
Technologies, Waldbronn, Karlsruhe, Germany) using elec-
trospray ionization (ESI, Jet Stream) in positive (+) and neg-
ative (−) polarity. Separation was performed using reversed 
phase (RP) chromatography with a Zorbax Eclipse XDB-
C18 column (2.1 × 100 mm, 1.8 µm, Agilent Technologies, 
Palo Alto, CA, USA). The column temperature was 50 °C 
and flow rate 0.4 ml/min. Mobile phase consisted either 
water (A) or methanol (B) both with 0.1% (v/v) formic acid. 
The gradient was as follows: 2% B followed by a gradient to 
100% B in 10 min, an isocratic step at 100% B for 4.5 min 
and 2% B for 2 min. Hydrophilic interaction (HILIC) chro-
matographic separation was performed on Acquity UPLC® 
BEH Amide column (2.1 × 100 mm, 1.7 µm, Waters Corpo-
ration, Milford, MA). The column temperature was 45 °C 
and flow rate 0.6 ml/min. Mobile phase consisted of 50% v/v 
acetonitrile in water (A) or 90% v/v acetonitrile in water (B) 
both with 20 mM ammonium formate buffer. The gradient 
was as follows: 100% B for 2.5 min followed by a gradient to 
0% B in 10 min and 100% B for 2.5 min. The sample volume 
of 2.0 µl was injected for each chromatographic run.
The ESI source operated using the following condi-
tions: capillary voltage 3500 V, nozzle voltage 1000 V, 
fragmentor voltage 100 V, skimmer 45 V, nebulizer pres-
sure 45 psi, drying gas temperature 325 °C and flow 10 l/
min and sheath gas temperature 350 °C and flow 11 l/min. 
Mass data were acquired with scan time of 600 ms over a 
50–1600 m/z range. For automatic MS/MS analyses, four 
ions with the highest intensities were selected for fragmen-
tation from every precursor scan cycle where precursor 
isolation width was set to 1.3 Da. Selected precursor ions 
were excluded after two product ion spectra and released 
after a 0.25-min hold. Precursor scan time either ended at 
20,000 counts or after 500 ms, depending on the ion inten-
sity. Product ion scan time was 500 ms. Collision energies 
were 10 V, 20 V and 40 V. Continuous internal calibration 
was performed during analyses to assure the desired mass 
accuracy. The reference ions from infusion solution were 
m/z 121.05087300 and 922.00979800 for positive mode 
and m/z 112.985587 and 966.000725 for negative mode. 
For the quality assurance of the chromatographic and mass 
spectrometry runs, QC mixed sample were injected at the 
beginning of the analysis and after every 9 samples. Sepa-
rate dog QC and human QC samples were analyzed in 
the beginning of the corresponding analysis to provide 
the MS data, and used for the automatic data-dependent 
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MS/MS analyses. The data acquisition was accomplished 
with MassHunter Acquisition B.05.01 software (Agilent 
Technologies).
2.5  Non‑targeted metabolomics data preprocessing
The LC–MS raw data from four different analytical 
modes (RP+, RP−, HILIC+, HILIC−) was exported to 
MassHunter Qualitative Analysis B.07.00 (Agilent Tech-
nologies, USA) for feature extraction and peak picking 
combined with chromatographic alignment across all 
data files per mode. To remove the redundant and non-
specific information considered as background noise, 
peaks with ion abundance less than 10,000 were excluded 
from further analysis. The feature files were imported as 
compound exchange format (.cef-files) into Agilent Mass 
Profiler Professional software (MPP version 13.1.1, Agi-
lent Technologies) for compound alignment yielding a 
peak list which was exported to Microsoft Excel 2016. 
Altogether, 8375 molecular features were collected in the 
four analytical modes. Out of those, molecular features 
that were present in at least 50% of the samples in either 
of the sample groups (5468 features) were considered for 
metabolite identification. Principal component analysis 
was performed using SIMCA (version 15, Umetrics).
2.6  Metabolite identification
The putative metabolite identification was performed using 
an open-source software, MS-DIAL (RIKEN PRIMe). Col-
lected MS/MS data was converted as.abf-files using Analysis 
Base File Converter program (Reifycs Inc.) and converted 
files were imported to MS-DIAL (versions 2.66 to 3.12). 
Public databases, Metlin and MassBank of North America 
(MoNA), and in-house LC–MS/MSMS standard library 
were downloaded to MS-DIAL for utilization of retention 
time, accurate mass, isotope ratio and MS/MS spectrum 
information for peak and metabolite identification. The 
built-in MS-DIAL library was utilized for lipid identifica-
tion. Each matched spectrum was manually inspected. The 
guidelines from Sumner et al. (2007) were used for ranking 
metabolite identifications as follows: Compounds in identifi-
cation level 1 were verified by comparing exact mass, reten-
tion time and MS/MS fragmentation spectra with in-house 
LC–MS/MSMS standard library. Compounds in level 2 were 
matched with exact mass and MSMS spectra from public 
databases mentioned above. MassHunter Profinder B.08.00 
software (Agilent Technologies) was applied for targeted 
feature extraction to minimize the appearance of false nega-
tive features implemented with the manual inspection and 
integration of the targeted feature.
3  Results
With the aim to explore salivary metabolite composition 
in dog and human, we focused on 5468 metabolic features 
collected with four analytical modes using a non-targeted 
metabolomics approach. A total of 211 metabolites were 
identified (Table 1) including both endogenous and exog-
enous compounds. Among those, 31 metabolites (14.6%) 
were found only in dog saliva, and 9 metabolites (4.2%) only 
in human saliva (Fig. 1). The identities of 69 metabolites 
were verified as level 1 identification (Sumner et al. 2007) 
whereas 142 metabolites were in identification level 2. Char-
acteristics and reference spectra for all identified metabolites 
in human and dog saliva are given as supplementary material 
(S1). The identified metabolites were classified as amino 
acids, amino acids derivatives, biogenic amines, lipids and 
carnitines, nucleic acid subunits, organic acids, small pep-
tides, chemicals, and other metabolites.
The major difference between the human and dog saliva 
metabolites was observed in the lipid group. Dog saliva 
contained 25 lipids or lipid-like molecules (i.e. carnitines), 
which were absent in the human saliva, including 11 phos-
phatidylcholines (PC), 6 phosphatidylethanolamines (PE), 
3 lysophosphatidylethanolamines (LPE), 2 lysophosphati-
dylcholines (LPC), 1 diacylglycerol (DAG) and 2 acyl-
carnitines. In contrast, small peptides, including mostly 
dipeptides, were more prevalent in human when compared 
to canine saliva. Dogs were completely lacking eight of the 
34 identified small peptides, and in total, 13 dipeptides had 
minor ion abundance in the dog saliva.
Both the dog and human saliva contained 15 of the 20 
generic amino acids. However, asparagine, cysteine, glycine, 
methionine and valine were not detected from the saliva of 
both species. The group of amino acid derivatives included 
ten metabolites. Among those, gamma glutamylglutamic 
acid was detected only in humans, and phenylacetylglycine 
only in canines. Besides amino acids and their derivatives, 
asymmetric dimethylarginine (ADMA), cadaverine, carnos-
ine, creatinine, histamine, spermidine and taurine were iden-
tified as biogenic amines. Those seven metabolites and eight 
different nucleic acid subunits were detected in both spe-
cies. Furthermore, canine saliva contained also one unique 
organic acid which was identified as pyrocatechol sulfate, 
and four other compounds named quinaldic acid, sphinga-
nine, sphingosine and usnic acid.
The entity of identified metabolites in canine and 
human saliva indicate partially comprised species-specific 
metabolic profiles (Table 1). In addition, a large variation 
in ion abundance within and between the identified saliva 
metabolites were observed in both species. Inter-individual 
variation and sample variation is shown with descriptive 
statistics in the supplementary material (S2). Furthermore, 
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Table 1  Identified metabolites in dog and human saliva in the non-targeted LC–MS analysis
Compound ID
Min Median Max Min Median Max
Amino acids
alanine 1 11621 37378 60490 13180 22480 40910
arginine 1 <10000 214558 654257 436614 1409422 2045075
aspartic acid 1 <10000 19530 56048 66610 249145 399489
glutamic acid 1 45808 352114 795587 92510 219896 477880
glutamine 1 172434 636094 1025305 85529 149544 318895
histidine 1 18000 509729 1065260 354376 488143 1069618
isoleucine 1 13531 324410 752675 31420 140750 246619
leucine 2 24612 286748 458104 20697 119312 196690
lysine 1 <10000 58618 144231 57367 321507 489095
phenylalanine 1 10952 279868 517735 342100 592727 1013511
proline 1 51145 296961 501040 261167 3878169 11401076
serine 2 10401 131521 203482 <10000 37455 88258
threonine 1 <10000 108277 173863 11676 23103 58526
tryptophan 1 <10000 44538 64061 <10000 <10000 34288
tyrosine 1 <10000 25757 41843 79017 183192 412868
Amino acid derivatives
1-methyl-histidine 1 <10000 60565 129019 11191 18643 50624
3-methyl-histidine 2 <10000 23990 73519 <10000 <10000 43698
5-aminovaleric acid betaine 1 12428 100529 346778 39681 110597 561505
carnitine 1 167694 1081252 1965566 810251 1485396 5209412
citrulline 1 18649 480638 774749 148079 360197 665101
creatine 1 779746 2402765 4766552 1070832 1599528 2560989
gamma glutamylglutamic acid 2 0 0 0 <10000 23557 101558
glycinebetaine 1 3641697 10717865 21103608 450155 1191462 2241265
ornithine 1 <10000 53746 268798 112063 199787 369461
phenylacetylglycine 2 19069 98686 382722 0 0 0
Biogenic amines
asymmetric dimethylarginine 2 <10000 93638 192806 12057 19586 34784
cadaverine 1 <10000 <10000 70675 20062 106938 336618
carnosine 1 <10000 77531 345281 <10000 <10000 14069
creatinine 1 <10000 3595432 10086481 <10000 1768218 2807040
histamine 1 <10000 <10000 20555 <10000 27233 213795
spermidine 1 <10000 41291 474831 0 346 1729
taurine 2 11922 112591 221966 33028 62705 83051
Lipids and carnitines
acetylcarnitine 1 65986 876765 2350521 <10000 192280 544614
acylcarnitine C16:0 1 <10000 70459 131534 0 0 0
acylcarnitine C18:0 1 20847 108243 224379 235 1271 2876
acylcarnitine C18:1 2 12269 83360 151949 0 0 0
azelaic acid 1 55255 142717 327229 37854 45207 56463
DAG 34:1 2 <10000 205691 822295 <10000 <10000 23115
DAG 34:2 2 65044 190939 862855 <10000 <10000 15559
DAG 36:3 2 73002 525301 2066243 <10000 <10000 23245
DAG 36:4 2 27386 236542 1097107 <10000 <10000 20966
DAG 38:4 2 52681 237655 907217 0 0 0
FA 15:0 2 42503 381984 1221547 37879 71890 127786
FA 16:0 2 1904573 2225850 2935780 1741092 1969314 2418832
FA 16:1 2 99647 947405 5787185 84217 278554 769808
FA 17:0 1 83142 124843 303479 68962 84249 158464
FA 17:1 2 24010 114688 419195 14253 34183 68761
FA 18:0 1 1906062 2265398 3147739 1762724 2137965 2902604
FA 18:1 1 496478 1830159 3901249 303215 485606 1395954
FA 18:2 2 122906 697812 1022533 86616 245000 857574
FA 18:3 2 <10000 65541 148335 <10000 16226 73462
FA 20:0 1 14102 46432 65739 19776 31424 55360
FA 20:1 2 29563 163202 441862 13801 17572 37779
Dog Human
Level of ID
 S. Turunen et al.
1 3
  90  Page 6 of 12
Table 1  (continued)
Compound ID
Min Median Max Min Median Max
Dog Human
Level of ID
FA 20:2 2 16807 179383 325995 <10000 16496 48413
FA 20:3 2 25837 130995 271927 16123 33537 140139
FA 20:4 2 126220 1012611 1694682 <10000 87885 479090
FA 20:5 2 29051 82854 228736 <10000 11784 41867
FA 21:0 2 <10000 18796 125634 2349 3090 4398
FA 22:0 2 15540 28550 48955 <10000 10423 18567
FA 22:1 1 35515 120940 233114 <10000 <10000 11683
FA 22:2 2 <10000 57428 130210 1079 2239 4427
FA 22:3 2 <10000 43436 173654 1854 3440 8009
FA 22:4 2 17392 101471 180448 <10000 <10000 38537
FA 24:1 (n-9) 1 40284 90624 201122 1357 3363 7059
gamma-butyrobetaine 2 14949 248812 751914 228851 711345 1685899
glycerophosphocholine 1 24233 328573 928629 <10000 <10000 23768
hydroxypalmitic acid 2 77734 193115 445803 <10000 11255 17943
isobutyryl carnitine 2 13086 115881 874317 15871 45861 94737
isovalerylcarnitine 1 12599 141423 341344 29009 62403 402540
leucic acid 2 <10000 25422 41427 26369 59768 105831
LPC 16:0 2 95458 648254 16030733 <10000 <10000 19228
LPC 16:1 2 <10000 54524 138021 0 0 0
LPC 18:0 2 113515 455793 4515596 <10000 <10000 41702
LPC 18:1 2 <10000 373385 2099599 0 0 8504
LPC 18:2 2 23760 215712 639442 673 1492 3643
LPE 16:0 2 14886 57102 335617 1119 2268 7056
LPE 16:1 2 <10000 62830 486427 0 0 0
LPE 18:0 2 113221 315339 529906 <10000 <10000 12287
LPE 18:1 2 44841 229410 516071 1050 3011 5784
LPE 18:2 2 21575 100444 298766 0 0 0
LPE 20:4 2 32446 110101 456484 0 0 0
panthenol 2 <10000 45107 229860 326 1009 7555
PC 32:1 (16:0_16:1) 2 125717 433195 1881012 0 0 0
PC 32:1e (16:0e_16:1) 2 156372 808574 1960968 0 0 0
PC 34:1 (16:0_18:1) 2 <10000 959665 2183143 0 0 0
PC 34:2 (16:0_18:2) 1 527876 1679345 3151504 0 0 0
PC 34:2e (16:0e_18:2) 2 <10000 1311992 2878498 0 0 0
PC 34:3 (16:1_18:2) 2 <10000 132082 1016841 0 0 0
PC 36:2 (18:1_18:1) 2 <10000 1048913 2627064 0 0 0
PC 36:3 (18:1_18:2) 2 <10000 1427006 5155045 0 0 0
PC 36:4 2 <10000 247531 2210703 0 0 0
PC 38:4 (18:0_20:4) 2 <10000 853419 1552674 0 0 0
PC 38:5 (18:1_20:4) 2 <10000 448002 1111031 0 0 0
PC 38:5e (18:1e_20:4) 2 <10000 1129401 3377601 2370 4163 5414
PE 28:0 (13:0_15:0) 2 <10000 119668 317171 0 0 0
PE 30:0 (15:0_15:0) 2 <10000 107950 559716 92 514 1695
PE 32:1 (15:0-17:1) 2 37852 204677 437195 <10000 <10000 14513
PE 32:2 (16:1_16:1) 2 19175 158878 338527 0 0 0
PE 33:2 (15:0_18:2) 2 <10000 104006 234261 0 0 0
PE 34:2 (16:1_18:1) 2 <10000 315200 587195 <10000 <10000 13358
PE 36:2 (18:1_18:1) 2 59997 134283 299542 <10000 <10000 19097
PE 36:2e (18:1e_18:1) 2 51929 93390 246276 <10000 <10000 16125
PE 36:3 (18:1_18:2) 2 141166 230330 330667 0 0 0
PE 36:3e (18:2e_18:1) 2 131863 424557 1203428 6967 10393 18368
PE 36:4 (16:0_20:4) 2 77210 222944 387097 0 0 0
PE 36:4e (16:0e_20:4) 2 205650 378956 912821 <10000 <10000 17742
PE 36:5e (16:1e-20:4) 2 101753 176899 409725 <10000 12316 25173
PE 38:4 (18:0_20:4) 2 155607 393155 748449 2183 4915 11117
PE 38:4e (18:0e_20:4) 2 89687 307156 675664 482 1733 3541
PE 38:5 (18:1_20:4) 2 100884 296574 671320 0 0 0
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Table 1  (continued)
Compound ID
Min Median Max Min Median Max
Dog Human
Level of ID
PE 38:5e (18:1e_20:4) 2 408052 780956 1966641 <10000 13631 29876
PE 38:6e (18:2e_20:4) 2 267091 877130 1714394 <10000 <10000 13788
propionylcarnitine 1 29989 305075 652985 17116 69733 188291
sebacic acid 2 17955 29244 53705 13812 16413 23916
suberic acid 2 18493 36830 71278 10258 15860 18933
TAG 36:0 2 <10000 46413 325421 <10000 <10000 245965
TAG 38:0 2 <10000 16567 278288 <10000 <10000 72190
Nucleic acid subunits
2'-deoxy-cytidine 2 11574 121793 664924 <10000 <10000 12687
adenine 1 30862 546767 1140050 25195 182329 736118
adenosine 1 1165584 3535798 5904123 <10000 <10000 71880
cytidine 1 19218 341518 1218546 <10000 12904 208364
cytosine 1 <10000 26965 91078 <10000 13350 113782
guanine 2 <10000 36689 189630 <10000 <10000 14927
inosine 1 14277 433451 867561 <10000 28611 540480
N6-methyl-adenine 2 <10000 13774 50640 17787 50615 123176
Organic acids
4-guanidinobutanoic acid 1 269089 1392982 6177370 <10000 12942 25562
gamma-aminobutyric acid (GABA) 1 <10000 33837 64474 <10000 58789 576304
indoxyl sulfate 1 <10000 47357 305682 <10000 <10000 12160
lactic acid 2 <10000 122285 225557 <10000 36476 86772
pyrocatechol sulfate 2 113205 1745700 3459574 0 0 0
succinic acid 1 45409 140947 229175 93984 476081 797934
Other metabolites
1-methylnicotinamide 1 10128 161587 389096 <10000 <10000 14391
2-amino-1-phenylethanol 2 <10000 40291 103424 106355 192183 325172
2-amino-2-methyl-1-propanol 2 <10000 107208 587120 <10000 <10000 38069
3-indoleacetic acid 1 <10000 14938 37641 <10000 39463 175354
4-hydroxybenzaldehyde 1 <10000 29604 186914 <10000 <10000 13761
4-methylpyridine 2 481 2233 8898 <10000 22131 98581
5-aminovaleric acid 1 102880 508819 1371563 1149976 4817223 7408576
allantoin 1 91518 228324 647239 34597 63745 264543
caffeine 1 <10000 <10000 24719 234706 974548 1881117
choline 2 2836825 16398828 27260268 <10000 5041236 8221382
hydroxyphenyllactic acid 1 <10000 47289 118171 16951 59103 99507
kynurenic acid 1 42796 326080 961407 247 746 1533
N-acetylgalactosamine 4-sulfate 2 <10000 56180 126171 <10000 <10000 35013
N-acetylglucosamine 2 <10000 <10000 30449 56943 458389 1675208
N-acetylneuraminic acid 1 <10000 47849 176244 99750 245418 1643564
nicotinic acid 1 <10000 75651 175443 <10000 23384 106513
pantothenic acid 1 <10000 41614 103199 2409 5289 <10000
paraxanthine 1 <10000 <10000 36642 94530 398382 821307
phosphocholine 1 <10000 <10000 91148 <10000 261633 1142184
purine 2 82881 1493615 3907676 <10000 135236 186741
quinaldic acid 2 <10000 34591 195869 0 0 0
riboflavin 1 <10000 24184 66906 442 2112 <10000
sphinganine 1 23812 68181 122139 0 0 0
sphingosine 2 34958 188907 233951 0 0 0
theobromine 1 393 3354 <10000 32249 82651 226896
trigonelline 1 <10000 64859 226093 10243 378399 1645666
urea 2 <10000 <10000 172306 63048 104945 176103
urocanic acid 1 <10000 414615 588379 10900 40058 71136
usnic acid 2 <10000 41140 575241 0 0 0
xanthine 1 <10000 43955 117175 29150 158465 394638
Small peptides
arg-ile 2 <10000 22196 34949 18331 341025 710052
arg-phe 2 <10000 45418 297897 250431 744952 1458725
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the principal component analysis clearly separated the dif-
ferent species, however large variation was also observed 
within species (supplementary material S3). Example total 
ion chromatograms of salivary samples of dog and humans 
from all four analytical modes are shown in the supple-
mentary material (S4).
Table 1  (continued)
Compound ID
Min Median Max Min Median Max
Dog Human
Level of ID
arg-ser 2 109 1955 4214 166259 677600 1155202
gly-pro 2 921 7991 24520 59843 255965 656388
gly-tyr 2 0 0 0 10647 93537 242898
his-glu 2 0 0 0 22420 65996 203852
his-gly 2 110 1394 3470 14162 99402 279463
his-his 2 0 0 0 17697 45681 139994
his-ile/leu 2 <10000 11735 16672 <10000 11516 57709
his-ser 2 0 714 1540 50783 251538 532871
ile-ser 2 223 1249 3180 <10000 34407 83363
leu-leu 2 <10000 16538 44365 65277 367415 1188286
leu-phe 2 <10000 <10000 12514 45017 126515 254275
leu-tyr 2 0 609 2477 <10000 49692 142071
lys-phe 2 523 2711 5132 64608 180533 350198
lys-pro 2 0 0 0 <10000 12059 127461
phe-his 2 109 692 3021 49613 422751 760880
phe-ile/leu 2 892 2475 5046 <10000 12556 129260
phe-ile-arg 2 0 0 0 <10000 29575 177209
phe-phe 2 0 643 2844 19985 27603 66633
phe-tyr 2 <10000 17609 74288 <10000 34889 233467
pro-leu 2 0 0 0 <10000 85454 282915
pyroglu-pro 2 0 1647 5592 <10000 22740 131784
ser-ala 2 3800 8553 13588 <10000 74119 357110
ser-ala-arg 2 0 0 0 27032 236658 473215
ser-gln 2 0 0 0 16908 89025 194865
ser-leu 2 <10000 <10000 13591 <10000 55009 187601
ser-pro 2 <10000 14358 31931 59218 230405 1034273
thr-phe 2 0 313 1132 185038 350604 887569
tyr-arg 2 <10000 <10000 19613 65635 183701 1127841
tyr-gly 2 236 635 1812 50474 98522 256180
tyr-ile/leu 2 0 1734 4178 30825 72468 194831
val-arg 2 <10000 <10000 34841 11757 34742 122268
val-leu 2 <10000 14638 37038 30689 206065 882780
Chemical compounds
dibutyl adipate 2 45845 106927 655818 47565 64526 172698
diethanolamine 1 18671 63434 135897 <10000 33277 451781
diethylhexyl adipate 2 145957 1520708 7535913 58058 101414 1556448
diisodecyl phthalate 2 99927 277741 1640341 208712 222322 247443
dioctyl phthalate 1 434106 1873771 7066364 254467 269640 308677
dodecyl sulfate 2 145172 1097399 2697976 225102 632151 25249152
dodecylbenzenesulfonic acid 2 287702 873888 1751253 15936 213023 566013
linoleamide 2 11863390 30840156 60906180 23231544 31221685 38207392
myristamide 2 1686252 3648810 9409145 2751050 4606192 5908500
oleamide 2 48130344 91514384 132632448 72842344 85608764 100743984
palmitoleamide 2 5279505 12170688 23845604 9643438 12678565 16119980
pentaerythritol tetrakis(3,5-di-tert-
butyl-4-hydroxyhydrocinnamate)
2 34593 76145 213762 52410 76586 156358
phthalic acid mono-2-ethylhexyl ester 2 60347 74071 107216 106038 128498 163136
stearamide 2 3478602 9423142 19570576 7812933 10203003 12323552
triethanolamine 2 <10000 117186 4144601 <10000 29260 223469
tris(hydroxymethyl)aminomethane 2 <10000 175962 348895 <10000 180882 239265
Level of identification (ID) based on Sumner et al. (2007).
Minimum, median and maximum abundances are shown.
Ion abundance
Color
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4  Discussion
This study provides the first characterization of canine 
saliva metabolome and compares its content to the human 
saliva. We identified altogether 211 metabolites in 13 
dog and 14 human saliva samples. Dog saliva contained 
31 unique metabolites that were mostly lipids and lipid-
like molecules. This study demonstrates the feasibility of 
UHPLC-qTOF-MS in canine and human salivary metabo-
lomics. Exploitation of both, high-resolution precursor and 
fragmentation data in MS/MS, enables the identification of 
metabolites that typically exist in lower amounts in saliva 
than in serum.
Comparison of the content of canine and human saliva 
revealed differences in the salivary lipids and lipid-like 
molecules. PCs were not detected in our current analysis in 
the human saliva, and in addition, eight out of 18 PEs were 
absent or found with low ion abundance in the human saliva. 
However, previous studies have reported on PCs in human 
saliva (Dame et al. 2015). Likewise, our analytical method 
is capable of detecting PCs, as we have reported them earlier 
from e.g. human plasma, and therefore most likely other 
than methodological issues are the reason why they were 
not detected in the current analysis from human saliva. PCs 
and PEs are major phospholipids of the plasma membranes 
in animal cells. This result may indicate the presence of 
epithelial cell membranes from the oral cavity in the dog 
saliva samples. Other identified lipids also had lower ion 
abundance in the human saliva samples when compared with 
the canine samples. An exception was observed with the 
most abundant fatty acids in tissues, FA 16:0, FA 18:0 and 
FA 18:1, which were present with high ion signals also in 
the human samples. These findings agree with a quantitative 
study conducted by Larsson et al. (1996) where lipids were 
detected only in low concentrations in human saliva. Instead, 
the whole saliva was found to contain more free fatty acids 
and neutral lipids like di- and triglycerides than polar lipids, 
such as PCs or PEs (Larsson et al. 1996).
In contrast to lipids, small peptides were found pre-
dominantly in human saliva. Canine saliva included only 
13 clear signals from di- and tripeptides, whereas 34 were 
found from human samples. Small peptides in saliva origi-
nate from protein degradation induced by host and bacterial 
proteases (Liebsch et al. 2019). Thus, oral health status, and 
especially periodontitis, can affect the salivary dipeptides. 
In the present study, human participants were healthy, and 
according to dog owners’, the dogs were not reported to have 
any diseases with one exception (cataract). It is unclear if the 
different fasting time (12 h for dogs versus minimum of one 
hour for human participants) and/or oral health, combined 
with the differences in antimicrobial and homeostatic pro-
tein compositions between species, affect to peptide levels 
observed in this study. In addition, the differences in sample 
collection (e.g. using paraffin wax) and handling may have 
had an effect.
We identified six additional metabolites, which were pre-
sent only in the canine saliva. Those included sphingosine 
and its derivative sphinganine, which are the major bases of 
the sphingolipids in mammals. Metabolites included also 
phenylacetylglycine (amino acid derivative) and pyrocat-
echol sulfate (organic acid) which are reported to be nor-
mal human metabolites. Previously, pyrocatechol sulfate 
was detected in our platform not only in human plasma 
but also in dog plasma (Hanhineva et al. 2015; Puurunen 
et al. 2016). Moreover, we putatively identified usnic acid 
in dog saliva. Usnic acid originates from lichens and might 
be a trace from a dog food. On the contrary to endogenous 
metabolites, exogenous compounds in saliva are traces from, 
for example, food, cosmetics, drug intake and environment 
(Dame et al. 2015). We identified 16 chemical compounds in 
both species, including phthalates, which are used as plasti-
cizers. Furthermore, we identified two surfactants, dodecyl 
Fig. 1  Venn diagram displaying 
the shared and unique salivary 
metabolites by classes among 
the two species. Metabolite was 
annotated as unique when the 
ion abundance was confirmed 
as zero in all samples per study 
group. Unique metabolites 
with zero ion abundance were 
confirmed with the manual 
inspection and integration 
of the targeted feature using 
MassHunter Profinder B.08.00 
software (Agilent Technologies)
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sulfate and dodecylbenzenesulfonic acid, which are used in 
cosmetics and foods. In addition, fatty acid amides myrista-
mide, palmitoleamide, stearamide, oleamide and linoleam-
ide, were found with high ion abundance in both species. 
Although these compounds are recognized as endogenous 
plasma metabolites (Kim et al. 2019), the identified fatty 
acid amides are also known as lubricants, detergents and 
softeners which we have found to be derived from the filters 
used in sample preparation (data not shown). Thus, they are 
considered as contaminants in this study.
The identified metabolites in dog and human saliva were 
characterized by inter-individual variation. Several factors, 
such as diurnal variation, oral health status, physiological 
condition, gender, age and nutrition are known to have an 
influence on the metabolite composition of human saliva 
(Kawanishi et al. 2019; Liebsch et al. 2019; Mikkonen et al. 
2013). These factors should be investigated in dogs when 
the potential of saliva as a sample material for research and 
diagnostics is discussed as the differences in saliva metabo-
lites between dog breeds, age and sex remain unsolved in 
this study. Those above-mentioned factors have been iden-
tified as affecting the dog plasma metabolome (Lloyd et al. 
2016, 2017) and saliva proteome (Pasha et al. 2018). Never-
theless, saliva provides information from several organs and 
its utility as “the new blood” for the diagnosis and monitor-
ing of human systemic diseases has been studied through 
omics (Cuevas-Cordoba and Santiago-Garcia 2014). This 
could also be a case for dogs and veterinary medicine after 
overcoming the sampling problems and conducting meta-
bolic profiling with larger sample size.
There are some limitations in our study. Firstly, there is 
no standard operation procedure for collecting dog saliva. 
In this study, we designed the canine saliva sampling pro-
tocol according to the reviewed literature (Elmongy and 
Abdel-Rehim 2016; Lensen et al. 2015) which aimed to be 
the most appropriate for the LC–MS analysis. We observed 
that, even though the dogs were trained for showing their 
teeth and to cooperate with their owners, the collection of 
saliva was still tricky to execute due to the characteristic 
features of saliva being elastic and mucous. Therefore, 
alternative sampling techniques that are comfortable for 
the dogs and easy to perform, and which provide enough 
sample material, need to be developed. Secondly, the 
non-targeted LC–MS method yields semi-quantitative 
data suitable for identification and sample-wise compari-
son but does not provide exact quantities for the detected 
compounds in saliva. Therefore, when exact quantities are 
required, other analytical approaches, such as nuclear mag-
netic resonance spectroscopy (NMR) or targeted LC–MS 
methods should be applied. However, the low sensitivity of 
NMR compared to MS limits the detection of the salivary 
metabolites identified in this study with NMR technique. 
Furthermore, metabolite identification was focused to the 
compounds that were classified into identification level 1 
and level 2 according Sumner et al. (2007). A wide range 
of unidentified metabolites still exist in the canine saliva. 
This is evident according to our data, where in total over 
8000 molecular features were detected providing a couple 
of hundred identifications. The identification of the metab-
olites behind these molecular features remains a challenge, 
and only small fraction of measured molecular features can 
usually be identified in a non-targeted metabolomics study. 
In addition, the applied LC–MS method does not capture 
the whole canine saliva metabolome. Characterization of 
the whole canine saliva metabolome would require use 
of more diverse set of methods (e.g. NMR and GC–MS) 
(Dame et al. 2015). Thirdly, our human subjects were all 
women. For comparing the metabolomes between species, 
both genders should be included to the study populations 
despite studies reporting only quantitative differences in 
salivary metabolites between men and women (Okuma 
et al. 2017; Takeda et al. 2009). Moreover, more restricted 
age range could have reduced variation seen in the canine 
samples. Finally, comparability between human and canine 
salivary metabolite profiles would improve if more aspects 
of the study design including sampling protocol could be 
harmonized between the species.
In conclusion, we were able to identify 211 metabo-
lites in the dog and human saliva using non-targeted 
metabolite profiling. This study provides novel informa-
tion that encourages the continuation of the studies with 
larger cohorts. The results demonstrate the potential of 
dog saliva metabolome to be used in understanding, for 
example, disease pathology or changes in metabolism due 
to xenobiotics or nutrition. Furthermore, saliva could be a 
source of specific biomarkers also for canines’ oral health 
problems as well as other diseases, but further research 
is needed to establish and validate the canine saliva bio-
markers. Understanding the differences between dogs and 
humans will then allow the results to be extrapolated to 
human health.
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